Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30256950 | 1.00 | NSD2 (0.39) | NSD2HPGDSATMF2NAMPT | |
| SCHEMBL23949876 | 0.82 | GRM5 (0.36) | NSD2 | |
| SCHEMBL30353399 | 0.82 | GRM5 (0.36) | NSD2 | |
| SCHEMBL25861439 | 0.77 | HPGDS (0.52) | HPGDSNAMPTAKT1HDAC1 | |
| SCHEMBL23949875 | 0.76 | NSD2 (0.42) | NSD2NAMPTTNFIRAK4HDAC1 | |
| SCHEMBL30257441 | 0.75 | GRM5 (0.36) | — | |
| SCHEMBL25555922 | 0.75 | GRM5 (0.36) | — | |
| SCHEMBL25555925 | 0.75 | NSD2 (0.40) | NSD2AKT1 | |
| SCHEMBL25555998 | 0.73 | GRM5 (0.38) | NSD2AKT1 | |
| SCHEMBL25554366 | 0.73 | GRM5 (0.35) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| EP-4137481-A1 | ARYL OR HETEROARYL DERIVATIVE | Teijin Pharma Limited (JP) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021210650-A1 | ARYL OR HETEROARYL DERIVATIVE | 帝人ファーマ株式会社 | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | NSD2 3265/4885HPGDS 4264/4885ATM 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.